It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Antimicrobial resistance (AMR) and healthcare associated infections pose a significant threat globally. One key prevention strategy is to follow antimicrobial stewardship practices, in particular, to maximise targeted oral therapy and reduce the use of indwelling vascular devices for intravenous (IV) administration. Appreciating when an individual patient can switch from IV to oral antibiotic treatment is often non-trivial and not standardised. To tackle this problem we created a machine learning model to predict when a patient could switch based on routinely collected clinical parameters. 10,362 unique intensive care unit stays were extracted and two informative feature sets identified. Our best model achieved a mean AUROC of 0.80 (SD 0.01) on the hold-out set while not being biased to individuals protected characteristics. Interpretability methodologies were employed to create clinically useful visual explanations. In summary, our model provides individualised, fair, and interpretable predictions for when a patient could switch from IV-to-oral antibiotic treatment. Prospectively evaluation of safety and efficacy is needed before such technology can be applied clinically.
The decision to switch patients from intravenous to oral antibiotic therapy is important for the individual and wider society. Here, authors show a machine learning model using routine clinical data can predict when a patient could switch.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Imperial College London, Centre for Antimicrobial Optimisation, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); Imperial College London, AI4Health Centre for Doctoral Training, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); Imperial College London, Department of Computing, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); Imperial College London, National Institute for Health Research, Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111)
2 Imperial College London, Centre for Antimicrobial Optimisation, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); Imperial College London, National Institute for Health Research, Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); University of Liverpool, Faculty of Health & Life Sciences, Liverpool, UK (GRID:grid.10025.36) (ISNI:0000 0004 1936 8470)
3 Imperial College London, Centre for Antimicrobial Optimisation, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); Imperial College London, National Institute for Health Research, Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); Imperial College Healthcare NHS Trust, London, UK (GRID:grid.417895.6) (ISNI:0000 0001 0693 2181)
4 Imperial College London, Centre for Antimicrobial Optimisation, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); Imperial College London, National Institute for Health Research, Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); Imperial College London, Centre for Bio-inspired Technology, Department of Electrical and Electronic Engineering, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111)
5 Imperial College London, Centre for Antimicrobial Optimisation, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); Imperial College London, National Institute for Health Research, Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); University of Liverpool, Faculty of Health & Life Sciences, Liverpool, UK (GRID:grid.10025.36) (ISNI:0000 0004 1936 8470); Imperial College London, Department of Infectious Diseases, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111)
6 Imperial College London, Centre for Antimicrobial Optimisation, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); Imperial College London, National Institute for Health Research, Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111)